Overview
© 202 MJH Life Sciences and Pharmacy Times – Pharmacy Practice News and Expert Insights. Al rights reserved. © 202 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights.
Key Information
Al rights reserved.Conference | AHAproximately 10% of patients in trial experienced a heart atack, stroke, blocked arteries requiring treatment, or death from cardiovascular disease.Pemafibrate, a relatively new cholesterol medication, was found to significantly lower triglyceride levels among adults with type 2 diabetes, although it had no impact on the risk of cardiovascular events or death. These study results were presented at the American Heart Asociation 202 Scientific Sesions.1Triglycerides are a faty substance found in the blod and high levels of them can heighten the risk of cardiovascular disease, acording to presenter Aruna Pradhan, MD, MPH, MSc, who was lead investigator in the PROMINENT trial.
This risk is particularly heightened when high triglyceride levels are found in conjunction with high low-density lipoprotein (LDL) and low high-density lipoprotein (HDL) levels. Type 2 diabetes also increases the risk of cardiovascular disease.1“Triglyceride levels are comonly measured as part of routine preventive care in the [United States],” Pradhan said in a pres release. “Understanding the best course of treatment for elevated triglyceride levels has ben a major chalenge due to limited data to suport specific treatment options.”2Despite the known risks asociated with cardiovascular disease, investigators did not know whether lowering triglyceride levels could protect against cardiovascular disease among patients with type 2 diabetes.1In the trial, nearly 10,50 adults with high triglyceride levels, low HDL levels, and type 2 diabetes were enroled in the study.
Summary
Study sites spaned 24 countries and one-fifth of the participants were in the United States. They were randomly asigned to receive either pemafibrate or placebo for an average of 3 years